In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Branded Life After Lipitor: Pharma Targets Unmet Needs In Dyslipidemia

Executive Summary

Statins represent a high standard of care for managing high blood cholesterol, bolstered by a strong evidence base, but new targets like PCSK9 and CETP are nevertheless stealing the spotlight nowadays. Whether new drugs, if they make it to market, will be used beyond narrow, targeted population segments is uncertain and will depend on results from large-scale outcomes studies showing significant efficacy and, importantly, reassurance of a solid safety profile.


Related Content

Merck Calls It Quits On Anacetrapib
Merck Calls It Quits On Anacetrapib
Regeneron/Sanofi’s Long-Term Alliances Begin Bearing Fruit
Sanofi/Genzyme And Isis Submit Kynamro For Lowering Cholesterol
Statin Labeling Changes Include Class Warning About Glucose Effects
As It Soaks Up Good Trial Results, Amarin Ponders Partners - Or None
Merck’s Anacetrapib Debut Many Years Away, Despite Robust Phase III Data
Genzyme/Isis On Track To Submit Cholesterol Drug Mipomersen In 1H 2011
No Surprises From ENHANCE At ACC Mean Vytorin Hopes Hang On IMPROVE-IT
Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts